Article info

Download PDFPDF
Off-label use of bevacizumab in the treatment of retinal disease: ethical implications

Authors

  1. Correspondence to Landon James Rohowetz, University of Missouri - Kansas City School of Medicine, Kansas City, MO 64108, USA; ljrvx8{at}mail.umkc.edu
View Full Text

Citation

Rohowetz LJ
Off-label use of bevacizumab in the treatment of retinal disease: ethical implications

Publication history

  • Received December 1, 2018
  • Revised June 23, 2019
  • Accepted June 28, 2019
  • First published July 18, 2019.
Online issue publication 
October 15, 2019

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.